HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

MAP Kinase Kinase Kinases (MAP Kinase Kinase Kinase)

Mitogen-activated protein kinase kinase kinases (MAPKKKs) are serine-threonine protein kinases that initiate protein kinase signaling cascades. They phosphorylate MITOGEN-ACTIVATED PROTEIN KINASE KINASES; (MAPKKs) which in turn phosphorylate MITOGEN-ACTIVATED PROTEIN KINASES; (MAPKs).
Also Known As:
MAP Kinase Kinase Kinase; Kinases, MAP Kinase Kinase; MAP3 Kinases; Mitogen-Activated Protein Kinase Kinase Kinases; Kinase Kinase, MAPK-ERK; Kinase Kinases, MAPK-ERK; Kinase, MAP3; Kinase, MAPK-ERK Kinase; Kinase, MEK; Kinases, MAP3; Kinases, MAPK-ERK Kinase; Kinases, MEK; MAPK ERK Kinase Kinase; MAPK ERK Kinase Kinases; Mitogen Activated Protein Kinase Kinase Kinase; Mitogen Activated Protein Kinase Kinase Kinases; MAP3 Kinase; MAPK-ERK Kinase Kinase; MAPK-ERK Kinase Kinases; MAPKKK; MAPKKKs; MEK Kinase; MEK Kinases; MEKK; MEKKs; Mitogen-Activated Protein Kinase Kinase Kinase
Networked: 388 relevant articles (18 outcomes, 44 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Ichijo, Hidenori: 6 articles (01/2022 - 09/2005)
2. Czech, Michael P: 6 articles (01/2017 - 04/2009)
3. Kohno, Michiaki: 5 articles (04/2012 - 05/2003)
4. Wang, Wei: 4 articles (01/2022 - 10/2016)
5. Dummer, Reinhard: 4 articles (01/2019 - 02/2010)
6. Tsichlis, Philip N: 4 articles (01/2019 - 03/2008)
7. Danai, Laura V: 4 articles (01/2017 - 12/2015)
8. Roth Flach, Rachel J: 4 articles (01/2017 - 12/2015)
9. Eliopoulos, Aristides G: 3 articles (02/2022 - 05/2011)
10. Meier, Friedegund: 3 articles (03/2021 - 11/2013)

Related Diseases

1. Neoplasms (Cancer)
2. Melanoma (Melanoma, Malignant)
3. Pancreatic Neoplasms (Pancreatic Cancer)
4. Sarcoma (Soft Tissue Sarcoma)
5. Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
01/01/2019 - "KRAS is one of the driver oncogenes in non-small-cell lung cancer (NSCLC) but remains refractory to current modalities of targeted pathway inhibition, which include inhibiting downstream kinase MEK to circumvent KRAS activation. "
06/01/2013 - "To determine if addition of a Bcl-2 family inhibitor could increase the efficacy of a MEK inhibitor, we evaluated a panel of 53 non-small cell lung cancer and pancreatic cancer cell lines with the combination of navitoclax (ABT-263), a Bcl-2/Bcl-xL (BCL2/BCL2L1) antagonist, and a novel MAP kinase (MEK) inhibitor, G-963. "
01/01/2021 - "BRAF and Mitogen-activated protein kinase, extracellular signal-regulated kinase kinase (MEK) inhibitors, although being currently approved for melanoma, non-small cell lung cancer (NSCLC) and colon cancer, have reported activity across other various cancers harbouring BRAF aberrations. "
11/15/2004 - "This multicenter, open-label, phase II study was undertaken to assess the antitumor activity and safety of the oral mitogen-activated extracellular signal regulated kinase kinase (MEK) inhibitor, CI-1040, in breast cancer, colon cancer, non-small-cell lung cancer (NSCLC), and pancreatic cancer. "
10/01/2021 - "Hematologic paraneoplastic syndromes with extreme neutrophilia and eosinophilia are very rarely associated with adenocarcinoma of the lung. We describe a case of a 57-year-old female who presented with neutrophil- and eosinophil-predominant hyperleukocytosis and hypoxic respiratory insufficiency. Bone marrow biopsy confirmed metastatic adenocarcinoma, similar to the biopsy-proven adenocarcinoma of the lung. She was administered one dose of cytotoxic chemotherapy with carboplatin and pemetrexed and started on leukoreductive therapy with hydroxyurea. Molecular testing revealed a BRAF V600E mutation and she was started on dabrafenib and trametinib with significant clinical improvement. This is the first reported case of metastatic BRAF V600E mutated non-small cell lung cancer presenting with extreme neutrophilia and eosinophilia treated with a combination BRAF and mitogen-activated extracellular kinase (MEK) inhibitor."

Related Drugs and Biologics

1. Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)
2. Mitogens
3. Phosphotransferases (Kinase)
4. Proteins (Proteins, Gene)
5. Mitogen-Activated Protein Kinase Kinases (MEKs)
6. trametinib
7. Mitogen-Activated Protein Kinases
8. AZD 6244
9. Proto-Oncogene Proteins B-raf
10. Protein Kinases (Protein Kinase)

Related Therapies and Procedures

1. Drug Therapy (Chemotherapy)
2. Therapeutics
3. Immunotherapy
4. Spinal Injections